These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 7647223

  • 1. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin.
    Hoppensteadt DA, Jeske W, Fareed J, Bermes EW.
    Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S57-64. PubMed ID: 7647223
    [Abstract] [Full Text] [Related]

  • 2. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins.
    Bendz B, Hansen JB, Andersen TO, Ostergaard P, Sandset PM.
    Br J Haematol; 1999 Dec; 107(4):756-62. PubMed ID: 10606880
    [Abstract] [Full Text] [Related]

  • 3. Tissue factor pathway inhibitor release induced by defibrotide and heparins.
    Cella G, Sbarai A, Mazzaro G, Motta G, Carraro P, Andreozzi GM, Hoppensteadt DA, Fareed J.
    Clin Appl Thromb Hemost; 2001 Jul; 7(3):225-8. PubMed ID: 11441984
    [Abstract] [Full Text] [Related]

  • 4. Physical and pharmacologic manipulation of the vascular system as measured by the release of TFPI and other mediators of antithrombotic actions.
    Hoppensteadt DA, Jeske W, Fareed J, Nicolaides AN.
    Int Angiol; 1996 Mar; 15(1):39-46. PubMed ID: 8739535
    [Abstract] [Full Text] [Related]

  • 5. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action.
    Hansen JB, Sandset PM, Huseby KR, Huseby NE, Bendz B, Ostergaard P, Nordøy A.
    Br J Haematol; 1998 Jun; 101(4):638-46. PubMed ID: 9674734
    [Abstract] [Full Text] [Related]

  • 6. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.
    Alban S, Gastpar R.
    Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675
    [Abstract] [Full Text] [Related]

  • 7. Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy.
    Hansen JB, Sandset PM.
    Thromb Res; 1998 Aug 15; 91(4):177-81. PubMed ID: 9736420
    [Abstract] [Full Text] [Related]

  • 8. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.
    Holst J, Lindblad B, Bergqvist D, Hedner U, Nordfang O, Ostergaard P.
    Thromb Res; 1997 May 15; 86(4):343-8. PubMed ID: 9187023
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antithrombin III affinity dependence on the anticoagulant, antiprotease, and tissue factor pathway inhibitor actions of heparins.
    Jeske W, Lormeau JC, Callas D, Iqbal O, Hoppensteadt D, Fareed J.
    Semin Thromb Hemost; 1995 May 15; 21(2):193-200. PubMed ID: 7660142
    [Abstract] [Full Text] [Related]

  • 14. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J, Leong WL, Hoppensteadt DA, Jeske WP, Walenga J, Wahi R, Bick RL.
    Semin Thromb Hemost; 2004 Dec 15; 30(6):703-13. PubMed ID: 15630677
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Physiological function of tissue factor pathway inhibitor and interaction with heparins.
    Sandset PM, Bendz B, Hansen JB.
    Haemostasis; 2000 Dec 15; 30 Suppl 2():48-56. PubMed ID: 11251341
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs).
    Samama MM, Bara L, Gerotziafas GT.
    Haemostasis; 1994 Dec 15; 24(2):105-17. PubMed ID: 7959358
    [Abstract] [Full Text] [Related]

  • 20. Very low doses of unfractionated heparin potentiate the anti-Xa activity of low molecular weight heparin (enoxaparin).
    Pèrez-Requejo JL, Lucena-Solano O, Pérez-García M, Santarelli MT.
    Thromb Res; 1997 Feb 01; 85(3):259-65. PubMed ID: 9058500
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.